Immunology of Hematopoietic Stem Cell Transplant

References

• Anasetti C. (2008). What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation? Best Pract Res Clin Haematol, 21, 691–697
   PubMed Web of Science ®Google Scholar
• Antin JH. (2002). Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med, 347, 36–42
   PubMedGoogle Scholar
• Antoun A, Jobson S, Cook M, et al. (2009). Ethnic variability in human leukocyte antigen-E haplotypes. Tissue Antigens, 73, 39–45
   PubMedGoogle Scholar
• Arrieta-Bolaños E, Madrigal JA, Shaw BE. (2012). Transforming growth factor-β1 polymorphisms and the outcome of hematopoietic stem cell transplantation. Int J Immunogen, 39, 192–202
   PubMed Web of Science ®Google Scholar
• Askenasy N, Stein J, Farkas DL. (2007). Imaging approaches to hematopoietic stem and progenitor cell function and engraftment. Immunol Invest, 36, 713–38
   PubMedGoogle Scholar
• Barrett AJ, Rezvani K, Solomon S, et al. (2003). New developments in allotransplant immunology. Hematol Am Soc Hematol Educ Progr, 2003(1), 350–71
   Google Scholar
• Beatty PG, Clift RA, Mickelson EM, et al. (1985). Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med, 313, 765–71
   PubMed Web of Science ®Google Scholar
• Begovich AB, Erlich HA. (1995). HLA typing for bone marrow transplantation: New polymerase chain reaction-based methods. JAMA, 273, 586–91
   PubMed Web of Science ®Google Scholar
• Behar E, Chao NJ, Hiraki DD, et al. (1996). Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med, 334, 286–91
   PubMed Web of Science ®Google Scholar
• Beutler E. (2009). Hematopietic stem cell transplant in the future. In: Applelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4th ed. London: Blackwell Publishing Ltd
   Google Scholar
• Billingham RE. (1966/1967). The biology of graft-versus-host reactions. Harvey Lect, 62, 21–78
   PubMedGoogle Scholar
• Bosch M, Khan FM, Storek J. (2012). Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol, 19, 324–35
   PubMed Web of Science ®Google Scholar
• Boukouaci W, Busson M, Fortier C, et al. (2011). Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation. Front Immunol, 2, 74, 1–6
   Web of Science ®Google Scholar
• Burlingham WJ, Grailer AP, Heisey DM, et al. (1998). The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Engl J Med, 339, 1657–64
   PubMed Web of Science ®Google Scholar
• Champlin RE, Horowitz MM, van Bekkum DW, et al. (1989). Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood, 73, 606–13
   PubMed Web of Science ®Google Scholar
• Chien JW, Zhang XC, Fan W, et al. (2012). Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood, 119, 5311–19
   PubMed Web of Science ®Google Scholar
• Chiffoleau E, Walsh PT, Turka L. (2003). Apoptosis and transplantation tolerance. Immunol Rev, 193, 124–45
   PubMed Web of Science ®Google Scholar
• Chu YW, Gress RE. (2008). Murine models of chronic graft-versus-host disease: Insights and unresolved issues. Biol Blood Marrow Transplant, 14, 365–378
   PubMed Web of Science ®Google Scholar
• Claas FH, Gijbels Y, van der Velden-de Munck J, van Rood JJ. (1988). Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science, 241, 1815–17
   PubMed Web of Science ®Google Scholar
• Cutler C, Antin JH. (2001). Peripheral blood stem cells for allogeneic transplantation: A review. Stem Cells, 19, 108–117
   PubMed Web of Science ®Google Scholar
• Danzer M, Polin H, Proll J, et al. (2009). Clinical significance of HL A-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation, 88, 528–32
   PubMed Web of Science ®Google Scholar
• del Campo AB, Carretero J, Aptsiauri N, Garrido F. (2012). Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens, 79, 147–54
   PubMedGoogle Scholar
• Dickinson AM, Middleton PG, Rocha V, et al. (2004). Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol, 127, 479–90
   PubMed Web of Science ®Google Scholar
• Dzierzak-Mietla M, Markiewicz M, Siekiera U, et al. (2012). Occurrence and impact of minor histocompatibility antigens’ disparities on outcomes of hematopoietic stem cell transplantation from HLA-matched sibling donors. Bone Mar Res, Article ID 257086, 1–12
   Google Scholar
• El-Chennawi F, Kamel H, Mosaad YM, et al. (2006). Impact of CD31 mismatches on the outcome of hematopoeitic stem cell transplant of HLA-identical sibling. Hematology, 11, 227–34
   PubMed Web of Science ®Google Scholar
• El-Shennawi F, Hafez M, El-Tonbary Y, et al. (2003). Assessment of the effect of compatibility markers on bone marrow transplants in hematologic malignancies. Haema, 6, 65–72
   Google Scholar
• Ferrara JL, Deeg HJ. (1991). Review graft-versus-host disease. N Engl J Med, 324, 667–74
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Levine JE, Reddy P, Holler E. (2009). Graft-versus-host disease. Lancet, 373, 1550–61
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transp, 11, 945–56
   PubMed Web of Science ®Google Scholar
• Goulmy E. (2006). Minor histocompatibility antigens: From transplantation problems to therapy of cancer. Human Immunol, 67, 433–8
   PubMed Web of Science ®Google Scholar
• Hahn T, McCarthy PLJr, Zhang MJ, et al. (2008). Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol, 26, 5728–34
   PubMed Web of Science ®Google Scholar
• Harris AC, Kitko CL, Couriel DR, et al. (2013). Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Haematologica, 98, 179–84
   PubMed Web of Science ®Google Scholar
• Hashimoto D, Chow A, Greter M, et al. (2011). Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med, 208, 1069–82
   PubMed Web of Science ®Google Scholar
• Heinemann FM, Ferencik S, Ottinger HD, et al. (2004). Impact of disparity of minor histocompatibility antigens HA-1, CD31 and Cd49b in hematopoeitic stem cell transplantation of patients with chronic myeloid leukemia with sibling and unrelated donors. Transplantation, 77, 1103–06
   PubMed Web of Science ®Google Scholar
• Hill GR, Ferrara JL. (2000). The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood, 95, 2754–9
   PubMed Web of Science ®Google Scholar
• Hodgkinson AD, Millward BA, Demaine AG. (2000). The HLA-E locus is associated with age at onset and susceptibility to type 1 diabetes mellitus. Hum Immunol, 61, 290–5
   PubMed Web of Science ®Google Scholar
• Holler E, Rogler G, Herfarth, H. (2004). Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood, 104, 889–94
   PubMed Web of Science ®Google Scholar
• Hsu KC, Keever-Taylor CA, Wilton A, et al. (2005). Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood, 105, 4878–84
   PubMed Web of Science ®Google Scholar
• Hutchinson IV, Turner DM, Sankaran D, et al. (1998). Influence of cytokine genotypes on allograft rejection. Transplant Proc, 30, 862–3
   PubMed Web of Science ®Google Scholar
• Ilhan O, Arslan Ö, Arat M, et al. (1999). The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfus Sci, 20, 69–71
   PubMedGoogle Scholar
• Imanguli MM, Swaim WD, League SC, et al. (2009). Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood, 113, 3620–30
   PubMed Web of Science ®Google Scholar
• Iravani-Saadi M, Karimi MH, Yaghobi R, et al. (2014). Polymorphism of costimulatory molecules (CTLA4, ICOS, PD.1 and CD28) and allogeneic hematopoietic stem cell transplantation in Iranian patients. Immunol Invest, 43, 391–404
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol, 5, 987–95
   PubMed Web of Science ®Google Scholar
• Janssen EM, Lemmens EE, Wolfe T, et al. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature, 421, 852–6
   PubMed Web of Science ®Google Scholar
• Kaneda S, Takeishi K, Ayusawa D, et al. (1987). Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucl Acids Res, 15, 1259–70
   PubMed Web of Science ®Google Scholar
• Kernan NA, Collins NH, Juliano L, et al. (1986). Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood, 68, 770–3
   PubMed Web of Science ®Google Scholar
• Khan F, Agarwal A, Agrawal S. (2004). Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Trans, 34, 1–12
   PubMed Web of Science ®Google Scholar
• Korngold R, Sprent J. (1982). Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med, 155, 872–83
   PubMed Web of Science ®Google Scholar
• Korngold R, Sprent J. (1989). Selective allogenic donor T cell subsets in experimental bone marrow transplantation. Transplant Proc, 21(1 Pt 3), 2940–2
   Web of Science ®Google Scholar
• Koyama M, Kuns RD, Olver SD, et al. (2012). Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med, 18, 135–42
   Web of Science ®Google Scholar
• La Nasa G, Littera R, Locatelli F, et al. (2007). The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol, 139, 284–8
   PubMed Web of Science ®Google Scholar
• Lajoie J, Hargrove J, Zijenah LS, et al. (2006). Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis, 193, 298–301
   PubMed Web of Science ®Google Scholar
• Lapidot T, Dar A, Kollet O. (2005). How do stem cells find their way home? Blood, 106, 1901–10
   PubMed Web of Science ®Google Scholar
• Lim JY, Cho BS, Min CK, et al. (2014). Fluctuations in pathogenic CD4+ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease. Immunol Invest, 43, 41–53
   PubMed Web of Science ®Google Scholar
• Lin MT, Storer B, Martin PJ, et al. (2003). Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med, 349, 2201–10
   PubMed Web of Science ®Google Scholar
• Lin MT, Storer B, Martin PJ, et al. (2005). Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood, 106, 3995–4001
   PubMed Web of Science ®Google Scholar
• Linhares YPL, Pavletic S, Gale RP. (2013). Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help? Bone Marrow Transpl, 48, 203–09
   Google Scholar
• Lo Celso C, Scadden DT. (2011). The haematopoietic stem cell niche at a glance. J Cell Sci, 124, 3529–35
   PubMed Web of Science ®Google Scholar
• Locatelli F, Lucarelli B, Merli P. (2014). Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacol, 15, 23–36
   PubMed Web of Science ®Google Scholar
• Loiseau P, Busson M, Balere ML, et al. (2007). HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transpl, 13, 965–74
   PubMed Web of Science ®Google Scholar
• Lorenz E, Schwartz DA, Martin PJ, et al. (2001). Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 7, 384–7
   PubMed Web of Science ®Google Scholar
• Mackall CL, Hakim FT, Gress RE. (1997). T-cell regeneration: All repertoires are not created equal. Immunol Today, 18, 245–51
   PubMedGoogle Scholar
• Marsh SG. (2012). Nomenclature for factors of the HLA system. Inter J Immunogen, 39, 370–2
   Google Scholar
• Martin PJ. (2009). Overview of hematopoietic cell transplantation immunology. In: Appelbrum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4th ed. Oxford, UK: Wiley-Blackwell
   Google Scholar
• Martin PJ, Pavletic SZ. (2009). Biology and management of chronic graft-versus-host disease. Cancer Treat Res, 144, 277–98
   PubMedGoogle Scholar
• Mattsson J, Ringdén O, Storb R. (2008). Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 14, 165–70
   PubMed Web of Science ®Google Scholar
• Matzinger P. (2002). The danger model: a renewed sense of self. Science, 296, 301–05
   PubMed Web of Science ®Google Scholar
• Merad M, Collin MP, Engleman EG. (2009). Dendritic cells in hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, eds. Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation, 4th ed. Oxford, UK: Wiley-Blackwell
   Google Scholar
• Middleton D, Gonzalez F. (2010). The extensive polymorphism of KIR genes. Immunology, 129, 8–19
   PubMed Web of Science ®Google Scholar
• Middleton PG, Cullup H, Cavet J, et al. (2003). Estrogen receptor alpha gene polymorphism associates with occurrence of graft versus host disease and reduced survival in HLA identical sib-allo BMT. Bone Marrow Transplantation, 32, 41–7
   PubMed Web of Science ®Google Scholar
• Miller JS, McCullar V. (2001). Human natural killer cells with polyclonal lectin and immunoglobulin-like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood, 98, 705–13
   PubMed Web of Science ®Google Scholar
• Miller JS, Warren EH, van den Brink MR, et al. (2010). NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant, 16, 565–86
   PubMed Web of Science ®Google Scholar
• Mosaad YM, Abdel-Dayem Y, El-Deek BS, El-Sherbini SM. (2011). Association between HLA-E *0101 homozygosity and recurrent miscarriage in Egyptian women. Scand J Immunol, 74, 205–09
   PubMed Web of Science ®Google Scholar
• Mosaad YM, Kamel H. (2005). HLA-DPB1 mismatch and acute graft-versus host disease in HLA-identical sibling donors. Egypt J Immunol, 12, 21–8
   PubMedGoogle Scholar
• Mullighan CG, Heatley S, Doherty K, et al. (2002). Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood, 99, 3524–9
   PubMed Web of Science ®Google Scholar
• Murai M, Yoneyama H, Harada A, et al. (1999). Active participation of CCR5 (+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest, 104, 49–57
   PubMed Web of Science ®Google Scholar
• Murphy N, Diviney M, Szer J, et al. (2006). Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant, 37, 773–9
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. (2014). PDQ® Childhood Hematopoietic Cell Transplantation. Bethesda, MD: National Cancer Institute. Date last modified <04/08/2014>. Available at: http://cancer.gov/cancertopics/pdq/treatment/childHCT/HealthProfessional [last accessed 24 Jun 2014]
   Google Scholar
• Nilsson SK, Simmons PJ. (2004). Transplantable stem cells: home to specific niches. Curr Opin Hematol, 11, 102–06
   PubMed Web of Science ®Google Scholar
• Nowak J, Graczyk-Pol E, Mika-Witkowska R, et al. (2007). Efficacy of bone marrow donor searches performed by Institute of Haematology and Transfusion Medicine in domestic and foreign registries in 1999–2006 for the patients with acute and chronic leukemia. Postepy Nauk Med, 20, 298–303
   Google Scholar
• Nowak J. (2008). Role of HLA in hematopoietic SCT. Bone Marrow Transplant, 42, S71–6
   Web of Science ®Google Scholar
• Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y. (2004). Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant, 34, 897–9
   PubMed Web of Science ®Google Scholar
• Oevermann L, Lang P, Feuchtinger T, et al. (2012). Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann NY Acad Sci, 1266, 161–70
   PubMed Web of Science ®Google Scholar
• Papayannopoulou T. (2003). Bone marrow homing: the players, the playfield, and their evolving roles. Curr Opin Hematol, 10, 214–19
   PubMed Web of Science ®Google Scholar
• Parham P. (2005). MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol, 5, 201–14
   PubMed Web of Science ®Google Scholar
• Parmar S, Ritchie DS. (2014). Allogeneic transplantation as anticancer immunotherapy. Curr Opin Immunol, 27, 38–45
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Wang Z, Horowitz MM, Gale RP. (2010). Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl, 2010, 87–105
   Google Scholar
• Patriarca F, Skert C, Sperotto A, et al. (2006). The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol, 34, 389–96
   PubMed Web of Science ®Google Scholar
• Perreault C, Décary F, Brochu S, et al. (1990). Minor histocompatibility antigens. Blood, 76, 1269–80
   PubMed Web of Science ®Google Scholar
• Petersdorf EW. (2013). Genetics of graft-versus-host disease: the major histocompatibility complex. Blood Rev, 27, 1–12
   PubMed Web of Science ®Google Scholar
• Petersdorf EW, Hansen JA, Martin PJ, et al. (2001). Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med, 45, 1794–800
   Google Scholar
• Podgorny PJ, Liu Y, Ugarte-Torres A, et al. (2011). Immune cell subsets in haematopoietic cell transplant recipients associated with graft-versus-host disease or infections. EBMT Abstract. Bone Marrow Transpl, 46, S168
   Google Scholar
• Powers JM, Trobridge GD. (2013). Identification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies. J Stem Cell Res Ther, S3, 004, 1–15
   Google Scholar
• Powles R, Mehta J, Kulkarni S, et al. (2000). Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet, 335, 1231–7
   Google Scholar
• Randolph SS, Gooley TA, Warren EH, et al. (2004). Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood, 103, 347–52
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Liu C, et al. (2005). A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med, 11, 1244–49
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Bremchley JM, et al. (2003). Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102, 2892–900
   PubMed Web of Science ®Google Scholar
• Ringden O, Pavletic SZ, Anasetti C, et al. (2009). The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 113, 3110–18
   PubMed Web of Science ®Google Scholar
• Robien K, Bigler J, Yasui Y, et al. (2006). Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant, 12, 973–80
   PubMed Web of Science ®Google Scholar
• Rocha V, Franco RF, Porcher R, et al. (2002). Host defence and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplant. Blood, 100, 3908–18
   PubMed Web of Science ®Google Scholar
• Rocha V, Porcher R, Fernandes JF, et al. (2009). Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia, 23, 545–56
   PubMed Web of Science ®Google Scholar
• Rubinstein P. (2001). HLA matching for bone marrow transplantation–how much is enough? N Engl J Med, 345, 1842–44
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097–100
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Burchielli E, et al. (2006). Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol, 16, 404–11
   PubMed Web of Science ®Google Scholar
• Sebzda E, Mariathasan S, Ohteki T, et al. (1999). Selection of the T cell repertoire. Annu Rev Immunol, 17, 829–74
   PubMed Web of Science ®Google Scholar
• Sellami MH, Torjemane L, Espadas de Arias A, et al. (2010). Mismatch for the minor histocompatibility antigen HA-2 and GVHD occurrence in HLA-A*0201-positive Tunisian recipients of HSCs. Immunol Invest, 39, 611–20
   PubMed Web of Science ®Google Scholar
• Shaw BE, Arguello R, Garcia-Sepulveda CA, Madrigal JA. (2010). The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haematol, 150, 251–8
   PubMed Web of Science ®Google Scholar
• Shilling HG, McQueen KL, Cheng NW, et al. (2003). Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood, 101, 3730–40
   PubMed Web of Science ®Google Scholar
• Shpall EJ, Champlin R, Glaspy JA. (1998). Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transpl, 4, 84–92
   PubMedGoogle Scholar
• Skert C, Damiani D, Michelutti A, et al. (2009). Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: Results of a prospective study. Bone Marrow Transplant, 44, 729–37
   PubMed Web of Science ®Google Scholar
• Spierings E, Goulmy E. (2005). Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest, 115, 3397–400
   PubMed Web of Science ®Google Scholar
• Spierings E, Wieles B, Goulmy E. (2004). Minor histocompatibility antigens—big in tumour therapy. Trends Immunol, 25, 56–60
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Giokas C, Dinou A, Papassavas A. (2012). The role of HLA in cord blood transplantation. Bone Marrow Res 2012, Article ID 485160, 1–9
   Google Scholar
• Stolzel F, Hackmann K, Kuithan F, et al. (2012). Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation, 93, 744–9
   PubMed Web of Science ®Google Scholar
• Storb R, Prentice RL, Thomas ED, et al. (1983). Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol, 55, 573–85
   PubMed Web of Science ®Google Scholar
• Storek J, Geddes M, Khan F, et al. (2008). Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol, 30, 425–37
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Murata M, Onizuka M, et al. (2008). Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int J Hematol, 87, 451–8
   PubMed Web of Science ®Google Scholar
• Tamouza R, Busson M, Rocha V, et al. (2006). Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation, 82, 1436–40
   PubMed Web of Science ®Google Scholar
• Tamouza R, Rocha V, Busson M, et al. (2005). Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation, 80, 140–4
   PubMed Web of Science ®Google Scholar
• Ting C, Alterovitz G, Merlob A, Abdi R. (2013). Genomic studies of GVHD—lessons learned thus far. Bone Marrow Transplant, 48(1), 4–9
   PubMed Web of Science ®Google Scholar
• Toubai T, Sun Y, Luker G, et al. (2013). Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood, 121, 4231–41
   PubMed Web of Science ®Google Scholar
• Trendelenburg M, Gregor M, Passweg J, et al. (2001). ‘Altered immunity syndrome’, a distinct entity in long-term bone marrow transplantation survivors? Bone Marrow Transplant, 28, 1175–6
   PubMed Web of Science ®Google Scholar
• Tripathi P, Naik S, Agrawal S. (2006). HLA-E and immunobiology of pregnancy. Tissue Antigens, 67, 207–13
   PubMedGoogle Scholar
• Trowsdale J, Barten R, Haude A, et al. (2001). The genomic context of natural killer receptor extended gene families. Immunol Rev, 181, 20–38
   PubMed Web of Science ®Google Scholar
• van den Brink MR, Burakoff SJ. (2002). Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol, 2, 273–81
   PubMed Web of Science ®Google Scholar
• van Rood JJ, Loberiza FR, Zhang MJ, et al. (2002). Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood, 99, 1572–7
   PubMed Web of Science ®Google Scholar
• Verfuerth S, Peggs K, Vyas P, et al. (2000). Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood, 95, 3990–5
   PubMed Web of Science ®Google Scholar
• Vitale C, Chiossone L, Morreale G, et al. (2004). Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol, 34, 455–60
   PubMed Web of Science ®Google Scholar
• Vogt MHJ, van den Muijsenberg JW, Goulmy E, et al. (2002). The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood, 99, 3027–32
   PubMed Web of Science ®Google Scholar
• Waldman E, Lu SX, Hubbard VM, et al. (2006). Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood, 107, 1703–1
   PubMed Web of Science ®Google Scholar
• Warren EH, Deeg HJ. (2013). Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigen April, 81(4):183–93
   PubMedGoogle Scholar
• Weber JS, Kudchadkar RR, Yu B, et al. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol, 31, 4311–18
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. (2007). Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol, 25, 139–70
   PubMed Web of Science ®Google Scholar
• Welniak LA, Kuprash DV, Tumanov AV, et al. (2005). Peyer’s patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. Blood, 107, 410–12
   PubMed Web of Science ®Google Scholar
• Westerhuis G, van Pel M, Toes RE, et al. (2011). Chimerism levels after stem cell transplantation are primarily determined by the ratio of donor to host stem cells. Blood, 117, 4400–01
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M, et al. (2013). Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol, 24, 2174–80
   PubMed Web of Science ®Google Scholar
• Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. (2005). Leukocyte migration and graft-versus-host disease. Blood, 105, 4191–9
   PubMed Web of Science ®Google Scholar
• Zorn E, Wang KS, Hochberg EP, et al. (2002). Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res, 8, 2052–060
   PubMed Web of Science ®Google Scholar